Oncomatryx Biopharma key facts
as of Oct 2026- Developer of stroma-targeted precision drugs and diagnostics intended to fight against invasive tumours.
- Oncomatryx Biopharma is valued at approximately $111.8M as of Oct 2026 (last reported valuation).
- It has raised $146.0M; the latest was PE Growth/Expansion ($67.6M) in Mar 2026.
- Notable investors include European Innovation Council, INNVIERTE SICC, Basque Government, Bilbao Bizkaia Kutxa, Diputación Foral de Bizkaia — 9 tracked in total.
- Status: Privately Held (backing).
Oncomatryx Biopharma's last reported valuation, Mar 2022. Nothing priced has surfaced since.
- ·Watch Oncomatryx Biopharma: the Monday email on marks, rounds and moves
Oncomatryx Biopharma funding rounds
No funding rounds for Oncomatryx Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Oncomatryx Biopharma valuation
Oncomatryx Biopharma's last reported valuation was $112 million in Mar 2022. No priced round, secondary trade or fund mark has surfaced since.
Oncomatryx Biopharma investors
9 investors are on record for Oncomatryx Biopharma, including European Innovation Council, INNVIERTE SICC, Basque Government and Bilbao Bizkaia Kutxa.
About Oncomatryx Biopharma
Developer of stroma-targeted precision drugs and diagnostics intended to fight against invasive tumours. The company is aimed at discovering new mechanisms and proteins in the peritumoral stroma, the cells, and the extracellular matrix that surround the tumour and facilitate its invasiveness, resistance to treatment, and metastasis, enabling doctors to diagnose, prognosis, and fight against tumour invasiveness.
- Sector
- Healthcare
- HQ
- Derio, Spain
- Founded
- 2009
- Employees
- 36
- Website
- oncomatryx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.